The stock of Trinity Biotech plc (ADR) (NASDAQ:TRIB) hit a new 52-week low and has $5.84 target or 10.00% below today’s $6.49 share price. The 5 months bearish chart indicates high risk for the $152.91M company. The 1-year low was reported on Oct, 4 by Barchart.com. If the $5.84 price target is reached, the company will be worth $15.29 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 2.87 million shares traded hands or 4643.64% up from the average. Trinity Biotech plc (ADR) (NASDAQ:TRIB) has risen 30.55% since March 1, 2016 and is uptrending. It has outperformed by 21.31% the S&P500.
Analysts await Trinity Biotech plc (ADR) (NASDAQ:TRIB) to report earnings on October, 27. They expect $0.05 EPS, down 50.00% or $0.05 from last year’s $0.1 per share. TRIB’s profit will be $1.18M for 32.45 P/E if the $0.05 EPS becomes a reality. After $0.06 actual EPS reported by Trinity Biotech plc (ADR) for the previous quarter, Wall Street now forecasts -16.67% negative EPS growth.
Trinity Biotech plc (ADR) (NASDAQ:TRIB) Ratings Coverage
Out of 3 analysts covering Trinity Biotech (NASDAQ:TRIB), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $24 is the highest target while $20 is the lowest. The $22 average target is 238.98% above today’s ($6.49) stock price. Trinity Biotech has been the topic of 4 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Trinity Biotech plc (ADR) (NASDAQ:TRIB) earned “Buy” rating by TH Capital on Wednesday, July 29. The stock has “Outperform” rating given by Raymond James on Thursday, September 3. Craig Hallum downgraded the stock to “Hold” rating in Friday, October 23 report.
According to Zacks Investment Research, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.”
More notable recent Trinity Biotech plc (ADR) (NASDAQ:TRIB) news were published by: Barrons.com which released: “Trinity Biotech PLC ADR” on August 31, 2015, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on July 07, 2009, Quotes.Wsj.com published: “DOW JONES, A NEWS CORP COMPANY” on February 11, 2011. More interesting news about Trinity Biotech plc (ADR) (NASDAQ:TRIB) were released by: Benzinga.com and their article: “Mid-Morning Market Update: Markets Open Higher; Darden Profit Beats Estimates” published on October 04, 2016 as well as Barrons.com‘s news article titled: “Trinity Biotech Is on the Road to Recovery” with publication date: October 31, 2015.
TRIB Company Profile
Trinity Biotech plc (Trinity Biotech), incorporated on January 22, 1992, develops, acquires, makes and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) divisions of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two divisions: the Americas and Rest of World. Trinity Biotech is a well-known provider of raw materials to the life sciences and research industries around the world. Trinity Biotech markets its portfolio of approximately 850 products to clients in approximately 100 countries around the world, through its sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech’s diagnostic products is the Americas, which consists of North America and South America. Trinity Biotech also sells raw materials to the life sciences industry and research institutes around the world, through its subsidiary, Benen Trading Ltd., trading as Fitzgerald Industries. Trinity Biotech sells its products through its direct sales organizations in the United States, Brazil and the United Kingdom, and through a network of principal distributors and non-governmental bodies into approximately 100 countries around the world. The Company’s products are classified as POC, emergency medicine, clinical laboratory and blood bank screening.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.